Pluri Inc. PLUR
Regular-session close
Pre-market · Nov 20, 4:32 AM ET
- YTD
- -67.57%
- 1 year
- -75.13%
5D -0.2545 (-21.57%)
- Market cap
- 13.94M
- Revenue (ttm)
- 326.00K
- EPS (ttm)
- -2.65
- Shares out
- 5.56M
- Forward P/E
- -13.88
- YTD return
- -67.57%
- 1-year return
- -75.13%
- Volume
- 11.65K
- Avg volume
- 36.70K
- Open
- 0.9199
- Previous close
- 0.9152
- Day's range
- 0.9199 – 1.03
- 52-week range
- 0.85 – 4.12
- Beta
- 1.63
Key statistics
- 50-day average
- 4.92
- 200-day average
- 5.56
- Enterprise value
- 35.20M
- Price / sales
- 78.09
- Price / book
- 254.44
- Revenue growth
- -13.50%
- Free cash flow
- -12.82M
- Total cash
- 29.98M
- Total debt
- 29.61M
- Return on equity
- -206.07%
- Short % of float
- 0.17%
Fundamental scorecard
4 of 25 checks passed on PLUR’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 0 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -1.08 | — | — |
| Sep 18, 2024 | Jun 1, 2024 | 0.00 | -2.98 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -1.01 | — | — |
| Feb 12, 2024 | Dec 1, 2023 | 0.00 | -0.96 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -0.96 | — | — |
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, is composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and phase I trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services; cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food-tech, CDMO, and agtech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- pluri-biotech.com
News
Why Greenfire Resources Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session Pluri And ZEO ScientifiX Announce Strategic Agreement To Expand Parties US Manufacturing And Commercialization Platform Serving Regenerative Medicine, Aesthetics, Wellness, And Longevity Markets
Pluri To Sell EIB Loan To Its Chairman And Largest Shareholder Alejandro Weinstein, Who Will Replace The EIB As Lender
Your note
Sign in to keep a note on PLUR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABERMAN ZALMAN | Director | Stock Award(Grant) | Jan 22, 2024 | 1,627,830 |
| ABONY LORNE KENNETH | Director | Stock Award(Grant) | Jan 22, 2024 | 36,750 |
| BIRGER PINHAS DORON | Director | Stock Award(Grant) | Jan 22, 2024 | 59,900 |
| FRANCO-YEHUDA CHEN | Chief Financial Officer | Stock Award(Grant) | Sep 17, 2024 | 67,503 |
| LEVI RAMI AVRAHAM | Director | Stock Award(Grant) | Jan 22, 2024 | 57,100 |
| SHEMESH-RASMUSSEN MAITAL | Director | Stock Award(Grant) | Jan 22, 2024 | 58,150 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 0.44% | 24,625 | 112.78K | Sep 29, 2024 |
| Values First Advisors, Inc. | 0.25% | 14,040 | 64.30K | Sep 29, 2024 |
| Eversource Wealth Advisors, Llc | 0.04% | 2,000 | 9.16K | Sep 29, 2024 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 0.03% | 1,659 | 7.60K | Sep 29, 2024 |
| UBS Group AG | 0.02% | 1,360 | 6.23K | Sep 29, 2024 |
| Morgan Stanley | 0.01% | 487 | 2.23K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 3,147 | 14.41K | Oct 30, 2024 |
| Dimensional ETF Tr-Dimensional International Small Cap ETF | 0.00% | 16 | 73 | Jul 30, 2024 |
